Cargando…

Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies

Kidney transplant recipients (KTR) are at increased risk for COVID-19-associated complications. We aimed to describe the evolving epidemiology and outcome of PCR-documented SARS-CoV-2 infection in KTR followed at our institution from March 2020 to May 2022. The primary endpoint was hospitalization f...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadimitriou-Olivgeris, Matthaios, Cipriano, Ana, Guggisberg, Nicolas, Kroemer, Marie, Tschopp, Jonathan, Manuel, Oriol, Golshayan, Dela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576844/
https://www.ncbi.nlm.nih.gov/pubmed/36267693
http://dx.doi.org/10.3389/ti.2022.10721
_version_ 1784811619659808768
author Papadimitriou-Olivgeris, Matthaios
Cipriano, Ana
Guggisberg, Nicolas
Kroemer, Marie
Tschopp, Jonathan
Manuel, Oriol
Golshayan, Dela
author_facet Papadimitriou-Olivgeris, Matthaios
Cipriano, Ana
Guggisberg, Nicolas
Kroemer, Marie
Tschopp, Jonathan
Manuel, Oriol
Golshayan, Dela
author_sort Papadimitriou-Olivgeris, Matthaios
collection PubMed
description Kidney transplant recipients (KTR) are at increased risk for COVID-19-associated complications. We aimed to describe the evolving epidemiology and outcome of PCR-documented SARS-CoV-2 infection in KTR followed at our institution from March 2020 to May 2022. The primary endpoint was hospitalization for COVID-19-related symptoms or death within 28 days from diagnosis. Overall, 243 cases were included of which 68 (28%) developed the primary outcome. A significant decrease in the incidence of the primary outcome was observed (p < 0.001, r −0.342) during the study period. Anti-Spike monoclonal antibodies (mAbs) were administered as early treatment (within 5–7 days of onset of symptoms) in 101 patients (14 with casirivimab/imdevimab and 87 with sotrovimab). Among 145 patients who had received at least one vaccination dose before infection, 109 patients were considered as adequately vaccinated. Multivariate analysis revealed that the Charlson Comorbidity Index (P 0.001; OR 1.28, CI 1.11–1.48) was associated with the primary outcome, while early administration of mAbs (P 0.032; OR 0.39, CI 0.16–0.92) was associated with a better outcome, but not infection during the period of the omicron variant predominance or adequate vaccination.
format Online
Article
Text
id pubmed-9576844
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95768442022-10-19 Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies Papadimitriou-Olivgeris, Matthaios Cipriano, Ana Guggisberg, Nicolas Kroemer, Marie Tschopp, Jonathan Manuel, Oriol Golshayan, Dela Transpl Int Health Archive Kidney transplant recipients (KTR) are at increased risk for COVID-19-associated complications. We aimed to describe the evolving epidemiology and outcome of PCR-documented SARS-CoV-2 infection in KTR followed at our institution from March 2020 to May 2022. The primary endpoint was hospitalization for COVID-19-related symptoms or death within 28 days from diagnosis. Overall, 243 cases were included of which 68 (28%) developed the primary outcome. A significant decrease in the incidence of the primary outcome was observed (p < 0.001, r −0.342) during the study period. Anti-Spike monoclonal antibodies (mAbs) were administered as early treatment (within 5–7 days of onset of symptoms) in 101 patients (14 with casirivimab/imdevimab and 87 with sotrovimab). Among 145 patients who had received at least one vaccination dose before infection, 109 patients were considered as adequately vaccinated. Multivariate analysis revealed that the Charlson Comorbidity Index (P 0.001; OR 1.28, CI 1.11–1.48) was associated with the primary outcome, while early administration of mAbs (P 0.032; OR 0.39, CI 0.16–0.92) was associated with a better outcome, but not infection during the period of the omicron variant predominance or adequate vaccination. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9576844/ /pubmed/36267693 http://dx.doi.org/10.3389/ti.2022.10721 Text en Copyright © 2022 Papadimitriou-Olivgeris, Cipriano, Guggisberg, Kroemer, Tschopp, Manuel and Golshayan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Health Archive
Papadimitriou-Olivgeris, Matthaios
Cipriano, Ana
Guggisberg, Nicolas
Kroemer, Marie
Tschopp, Jonathan
Manuel, Oriol
Golshayan, Dela
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title_full Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title_fullStr Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title_full_unstemmed Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title_short Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
title_sort outcome of covid-19 in kidney transplant recipients through the sars-cov-2 variants eras: role of anti-sars-cov-2 monoclonal antibodies
topic Health Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576844/
https://www.ncbi.nlm.nih.gov/pubmed/36267693
http://dx.doi.org/10.3389/ti.2022.10721
work_keys_str_mv AT papadimitriouolivgerismatthaios outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT ciprianoana outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT guggisbergnicolas outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT kroemermarie outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT tschoppjonathan outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT manueloriol outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies
AT golshayandela outcomeofcovid19inkidneytransplantrecipientsthroughthesarscov2variantserasroleofantisarscov2monoclonalantibodies